Purity figures alone tell only part of the story. A nasal spray labeled "99% pure Semax" could contain anywhere from 1 mg/mL to 10 mg/mL of active peptide, a tenfold difference that fundamentally changes every dose calculation. Researchers evaluating Semax nasal spray research products: how to compare concentration, excipient disclosure, and analytical documentation need a structured framework, not just a headline number.

Key Takeaways

• Semax nasal spray concentration is expressed in mg/mL; a 0.1% solution equals 1 mg/mL and a 1% solution equals 10 mg/mL, always convert before comparing products.
• COA-measured net peptide content often differs from the label claim; reviewing actual tested values is essential for accurate dosing calculations.
• Excipient disclosure, including buffer type, pH, and preservative identity, varies widely between suppliers and directly affects formulation comparability.
• High-quality analytical documentation combines HPLC purity, MS identity confirmation, heavy metal screening, sterility testing, and endotoxin limits, not just a single purity percentage.
• COA accessibility models range from instant download to on-request portals; downloadable batch-specific documents with ISO-accredited lab credentials offer the strongest verification path.

---

Comparing Concentration Across Semax Nasal Spray Research Products

The single most consequential variable when comparing Semax nasal spray research products is concentration, yet it is frequently presented inconsistently across suppliers. Some vendors list total milligrams per bottle, others use percentage notation, and others specify micrograms per actuation. All three refer to the same underlying quantity, but only when converted to mg/mL do they become directly comparable.

A 0.1% Semax nasal spray contains 1 mg/mL of active peptide. A 1% spray contains 10 mg/mL. Russian clinical studies that established the foundational Semax research record typically used 0.1% (1 mg/mL) solutions, delivering 200-400 mcg intranasally per day. A 5 mL bottle at that concentration holds 5 mg total and delivers roughly 50-100 mcg per spray, yielding approximately 25-50 actuations at 100 mcg each.

Some commercial research products now sit at 1 mg/mL with 100 mcg per metered spray across a 10 mL bottle, a total of 10 mg per container. Others label 30 mg in a 10 mL bottle, placing concentration at 3 mg/mL. The table below illustrates how to normalize these figures:

Label Claim	Volume	Calculated mg/mL	Mcg per 100 µL Spray
5 mg bottle	5 mL	1.0 mg/mL	100 mcg
10 mg bottle	10 mL	1.0 mg/mL	100 mcg
30 mg bottle	10 mL	3.0 mg/mL	300 mcg
50 mg bottle	10 mL	5.0 mg/mL	500 mcg

Always verify whether the listed volume is the fill volume or the nominal bottle size. COA-measured net content can exceed the label claim, one batch labeled at 30 mg was independently tested and found to contain 33 mg, which shifts every dose calculation upward. Relying on the label alone introduces systematic error.

Beyond standard Semax, researchers should confirm the peptide variant. N-acetyl Semax amide (NA-Semax Amidate) is a structurally distinct analogue with different pharmacokinetic properties. It may be presented in an identical nasal spray format at 1 mg/mL, but it is not interchangeable with the classical heptapeptide for research comparison purposes. The COA identity section, not just the product name, is the authoritative source for confirming which compound is actually present.

---

Excipient Disclosure: What the Carrier Composition Reveals

Excipient transparency has emerged as one of the clearest differentiators among Semax nasal spray research products. The carrier solution, the liquid in which the peptide is dissolved, directly influences stability, mucosal tolerability, and the comparability of formulations across studies.

A fully disclosed excipient profile includes:

• Buffer identity (e.g., normal saline, phosphate-buffered saline)
• pH value (typically 5.5-7.0 for nasal formulations)
• Preservative (e.g., benzalkonium chloride at 0.01%)
• Solvent grade (e.g., lab-grade distilled water, sterile water for injection)

Some suppliers publish this information directly on the product page, specifying normal saline at pH 6.0 with benzalkonium chloride (BKC) at 0.01% as the antimicrobial preservative. This level of detail allows a researcher to assess whether the formulation is isotonic, whether the pH is within a range that preserves peptide integrity, and whether the preservative could interact with any assay being conducted.

Other suppliers focus their public-facing documentation entirely on peptide identity and purity, leaving excipient composition unstated. This is not necessarily a quality failure, the peptide itself may be excellent, but it limits formulation comparability and makes it harder to replicate or cross-reference research conditions.

"The carrier is not inert. pH, ionic strength, and preservative concentration all affect peptide stability and nasal absorption kinetics. Excipient disclosure is a research variable, not just a regulatory formality."

Container closure is a related but often overlooked factor. Metered-dose nasal pumps with defined actuation volumes (typically 100 µL) enable reproducible delivery. Simple dropper-top bottles do not. When comparing products, confirm whether the delivery device is a calibrated pump and what the stated actuation volume is.

---

Analytical Documentation Standards for Semax Spray Research Products

Evaluating Semax nasal spray research products: how to compare concentration, excipient disclosure, and analytical documentation ultimately depends on the depth and accessibility of the certificate of analysis. A single purity percentage is a starting point, not a complete picture.

Purity figures across current research suppliers range from approximately 98.5% to a claimed 100%. However, the more meaningful question is: what method produced that number, and what does the COA document beyond it?

A research-grade COA should include:

1. HPLC purity, with method details (e.g., RP-HPLC at 214 nm), retention time, and a defined specification threshold (e.g., ≥99.0% peak area)
2. Mass spectrometry identity, LC-MS or MALDI-MS confirming the expected molecular mass (Semax: approximately 813.9 Da for the full heptapeptide sequence)
3. Net peptide content, HPLC-quantified actual mass, not just label claim
4. Heavy metals, ICP-MS screening with a "not detected" or numerical result
5. Sterility or microbial testing, PCR-based or culture-based, with explicit pass criteria
6. Endotoxin, tested under USP guidelines with a defined EU/mL limit
7. Lot number and analysis date, batch-specific, not a generic template
8. Laboratory accreditation, ISO 17025 certification is the current benchmark

Some suppliers now offer panels that include all eight elements above, including fentanyl screens as an additional safety marker. Others provide identity and purity alone. The gap between these two documentation levels is significant for any serious research context.

COA accessibility also varies. Some vendors maintain downloadable COA libraries organized by batch ID and analysis date, enabling pre-purchase verification. Others issue batch-specific documents only through a support portal on request. Both models can yield legitimate documentation, but downloadable access reduces friction and allows faster cross-batch comparison.

When reviewing identity data, look for explicit mass values rather than generic confirmations. Semax's molecular formula is C₃₇H₅₁N₉O₁₀S (CAS 80714-61-0), with a monoisotopic mass of approximately 813.35 Da. A COA that reports a measured mass matching this value, and notes the absence of Met-sulfoxide oxidation products or truncated sequence variants, demonstrates a higher level of analytical rigor than one that simply states "identity confirmed."

Researchers exploring related peptide research categories, such as SS-31 mitochondrial research or ipamorelin spray products, will recognize that the same COA evaluation framework applies across nasal and injectable peptide formats. The same standards used to assess IPA Sermorelin stack research documentation, HPLC purity, MS identity, and lot traceability, translate directly to Semax nasal spray evaluation. Similarly, researchers reviewing SS-31 kidney health research products or aging support compounds will find that multi-method COA panels are becoming the expected standard across the research peptide sector.

---

Conclusion

Comparing Semax nasal spray research products: how to compare concentration, excipient disclosure, and analytical documentation requires moving beyond headline purity figures to a structured, multi-variable assessment.

Actionable next steps for researchers:

• Convert all concentration data to mg/mL before comparing products; do not rely on percentage notation or total bottle content alone.
• Request or download the batch-specific COA before purchase and confirm it includes HPLC purity with method details, MS identity with a numerical mass value, and a dated lot number.
• Verify excipient composition, buffer type, pH, and preservative identity, to ensure formulation comparability across research conditions.
• Confirm the peptide variant (standard Semax vs. NA-Semax Amidate or other analogues) using the identity section of the COA, not the product name alone.
• Prioritize suppliers using ISO 17025-accredited laboratories and offering multi-parameter panels that include heavy metal, sterility, and endotoxin testing.

As the research peptide market in 2026 continues to mature, suppliers offering transparent, multi-method documentation and full excipient disclosure are setting a higher benchmark. Applying this framework consistently protects research integrity and enables meaningful cross-product comparison.